Why do some microbiome therapies work in one trial but fail in another?
The biggest gap is inconsistent efficacy. In recurrent C. difficile infection, a defined 8-strain consortium (VE303) reduced recurrence to 13.8% compared to 36.4% with placebo in a phase 2 trial [1]. Yet another donor-derived product, CP101, had its phase 3 trial discontinued despite positive phase 2 data [1]. This inconsistency stems partly from donor variability: full-spectrum donor-dependent products like RBX7455 showed 80-100% success in a small phase 1 study [1], but relying on different donors means each batch can differ, making results hard to replicate.
Safety is another major gap. Fecal microbiota transplants (FMT) have transmitted drug-resistant E. coli bacteremia to a patient with cirrhosis [2], and there are ongoing concerns about transmitting pathogens or antibiotic-resistant organisms [1]. This risk is especially high in vulnerable populations like those with liver disease, where the gut barrier is already compromised [2]. The field is moving toward defined bacterial consortia (like VE303) or single strains (like ADS024) that are manufactured from clonal cell banks, which eliminates donor variability and reduces infection risk [1], but these products are still early-stage and face their own regulatory hurdles.
Can we make microbiome therapies consistent enough to be real drugs?
Standardization is a critical gap. Probiotics, often classified as dietary supplements in the US, suffer from batch-to-batch variability and lack of regulatory oversight [2]. For example, in liver disease, probiotics have shown mixed results—some open-label studies improved outcomes in hepatic encephalopathy, but a double-blind RCT only found a reduction in all-cause hospitalizations, not HE-related ones [2]. This inconsistency makes it hard for doctors to know which product to trust.
Defined bacterial consortia offer a path forward. Products like VE303 (8 clostridial strains) and MET-2 (40 bacterial species) are manufactured from clonal cell banks, ensuring each batch has the same composition [1]. MET-2 increased gut microbial diversity and showed a 'scaffolding effect,' helping recover microbes not even in the capsule [1]. However, even these face challenges: MET-2's developer decided against further development for C. diff due to a competitive market [1], showing that commercial viability is another gap. The field needs large-scale, longitudinal trials that compare different formulations head-to-head, which none of these studies provide.
Do we actually understand how these therapies work—and for whom?
A major evidence gap is mechanistic uncertainty. We know the gut microbiome affects the liver through bile acids, short-chain fatty acids (SCFAs), and immune molecules [2], and it influences the brain via the microbiota-gut-brain axis [3]. But exactly which bacterial strains or metabolites drive clinical improvement is often unclear. For instance, in diabetic gastroenteropathy, researchers propose a 'microbiota-ENS axis' where microbial metabolites target the enteric nervous system [4], but this is based mostly on preclinical data—human trials are lacking.
Personalization is another gap. Patients with the same disease (e.g., cirrhosis) have vastly different gut microbiomes [2]. Trial designs rarely account for this heterogeneity, which could explain why some patients respond and others don't. The review on microbiome therapeutics in liver disease explicitly calls for prespecified microbiome analysis and stratification in future trials [2]. Similarly, in depression, psychobiotics show promise in preclinical and early clinical work, but heterogeneity in strains, doses, and populations means we don't know which patients benefit most [3]. Without this knowledge, microbiome therapies remain a one-size-fits-all approach that often doesn't fit.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 4 in Q1 journals — selected as the most relevant from 6 studies that passed quality screening, drawn from 65 papers retrieved from a database of over 500 million.
Sources used in this answer
Future Microbiome Therapeutics for Clostridioides difficile Infection
In recurrent C. diff, a defined 8-strain consortium (VE303) reduced recurrence to 13.8% vs. 36.4% with placebo in a phase 2 trial, but another donor-derived product (CP101) had its phase 3 discontinued, highlighting inconsistent efficacy and the shift toward standardized, donor-independent products.
The Current and Future State of Microbiome Therapeutics in Liver Disease
In liver disease, FMT shows promise (e.g., improving cognition in hepatic encephalopathy) but one case transmitted drug-resistant E. coli bacteremia to a patient with cirrhosis, underscoring safety risks; the review calls for rigorous RCTs and notes probiotics suffer from batch variability due to supplement classification.
MICROBIOTA-GUT-BRAIN AXIS IN MAJOR DEPRESSION: PATHOPHYSIOLOGY AND PSYCHOBIOTIC INTERVENTIONS
In depression, modulation of the gut-brain axis via psychobiotics, prebiotics, and diet shows preclinical and early clinical promise, but heterogeneity in study designs, strains, and populations prevents firm conclusions; large-scale randomized trials are needed.
Microbiota and enteric nervous system crosstalk in diabetic gastroenteropathy: bridging mechanistic insights to microbiome-based therapies
In diabetic gastroenteropathy, the 'microbiota-ENS axis' is proposed as a central hub, with microbial metabolites (SCFAs, bile acids, tryptophan) targeting the enteric nervous system, but evidence is mostly preclinical; translational challenges and lack of human trials are key gaps.
Harnessing the Microbiome: CRISPR-Based Gene Editing and Antimicrobial Peptides in Combating Antibiotic Resistance and Cancer
CRISPR-based microbiome engineering and antimicrobial peptides offer potential to combat antibiotic resistance and cancer, but translation to clinical settings faces ethical, regulatory, and ecological hurdles; optimizing stability, delivery, and bioavailability are critical research gaps.